Ameriprise
IBRX icon

Ameriprise’s ImmunityBio IBRX Stock Holding History

Ameriprise’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$656K Buy
74,887
+10,364
+16% +$78.4K ﹤0.01% 3584
2026
Q1 		$495K Buy
64,523
+26,731
+71% +$183K ﹤0.01% 3592
2025
Q4 		$74.8K Buy
37,792
+6,495
+21% +$14.7K ﹤0.01% 4023
2025
Q3 		$77K Buy
31,297
+1,267
+4% +$3.26K ﹤0.01% 3992
2025
Q2 		$79.3K Sell
30,030
-8,774
-23% -$23.6K ﹤0.01% 3898
2025
Q1 		$117K Buy
38,804
+23,790
+158% +$72.1K ﹤0.01% 3862
2024
Q4 		$38.4K Buy
+15,014
New +$62.5K ﹤0.01% 4021
2024
Q3 		– Sell
-11,155
Closed -$70.5K – 3972
2024
Q2 		$70.5K Sell
11,155
-3,860
-26% -$25.4K ﹤0.01% 3802
2024
Q1 		$80.6K Sell
15,015
-6,085
-29% -$27.6K ﹤0.01% 3792
2023
Q4 		$106K Buy
+21,100
New +$66.2K ﹤0.01% 3808
2023
Q3 		– Sell
-22,400
Closed -$62.3K – 3919
2023
Q2 		$62.3K Buy
+22,400
New +$63.3K ﹤0.01% 3855
2023
Q1 		– Sell
-67,995
Closed -$345K – 3984
2022
Q4 		$345K Buy
+67,995
New +$373K ﹤0.01% 3537
2021
Q4 		– Sell
-27,615
Closed -$269K – 4005
2021
Q3 		$269K Sell
27,615
-520
-2% -$5.72K ﹤0.01% 3618
2021
Q2 		$402K Buy
28,135
+35
+0.1% +$578 ﹤0.01% 3536
2021
Q1 		$667K Buy
28,100
+490
+2% +$12.7K ﹤0.01% 3302
2020
Q4 		$368K Buy
+27,610
New +$266K ﹤0.01% 3438
2018
Q4 		– Sell
-11,850
Closed -$44K – 3703
2018
Q3 		$44K Buy
11,850
+240
+2% +$759 ﹤0.01% 3668
2018
Q2 		$35K Buy
+11,610
New +$43K ﹤0.01% 3609

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise's IBRX Position: Q2 2026 in Review

Ameriprise increased its ImmunityBio (IBRX) stake by 16% in Q2 2026, buying an estimated $78.4K and bringing the position to 74,887 shares worth $656K. The position accounts for ﹤0.01% of the portfolio, ranked #3584.

Ameriprise first reported a position in IBRX in Q2 2018 and has held it in 18 quarters since. The position peaked at $667K in Q1 2021. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Ameriprise held 74,887 shares of ImmunityBio worth $656K as of Q2 2026.
  • Ameriprise bought 10,364 ImmunityBio shares in Q2 2026, an estimated $78.4K.
  • ImmunityBio made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3584 holding.
  • Ameriprise first reported a position in ImmunityBio in Q2 2018 and has held it in 18 quarters since.
  • Ameriprise's ImmunityBio position peaked at $667K in Q1 2021.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.